Are Corporations Re-Defining Illness and Health? The Diabetes Epidemic, Goal Numbers, and Blockbuster Drugs

No abstract is available for this paper.

• Publication year

  2021

• Venue

  Journal of Bioethical Inquiry

• Publication date

  2021-09-01

• Fields of study

  Medicine, Business, Political Science

• Identifiers
  DOI 10.1007/s11673-021-10119-xPMID 34487285PMCID PMC8568684
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ending Epidemics

  2023cited by this paper
• Risk of Progression to Diabetes Among Older Adults With Prediabetes.

  2021cited by this paper
• Consensus statement by the American Association of Clinical Endocrinology (AACE) and the American Head and Neck Society Endocrine Surgery Section (AHNS‐ES) on Pediatric Benign and Malignant Thyroid Surgery

  2021cited by this paper
• Communicating emerging risks of SGLT2 inhibitors—timeliness and transparency of medicine regulators

  2020cited by this paper
• CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.

  2020cited by this paper
• Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018.

  2020cited by this paper
• Symposium Lead Essay—Conflict of Interest: Opening Up New Territories

  2020cited by this paper
• CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.

  2019cited by this paper
• Prescription Drug Use Among Adults Aged 40-79 in the United States and Canada.

  2019cited by this paper
• Financial conflicts of interest in systematic reviews: associations with results, conclusions, and methodological quality.

  2019cited by this paper
• RE: CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.

  2019cited by this paper
• Corporate Logic in Clinical Care: The Case of Diabetes Management.

  2019cited by this paper
• Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.

  2019cited by this paper
• Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

  2019cited by this paper
• Measuring What Matters in Diabetes.

  2019cited by this paper
• 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020

  2019cited by this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020

  2019cited by this paper
• Benefits and harms of intensive glycemic control in patients with type 2 diabetes

  2019cited by this paper
• Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.

  2019cited by this paper
• Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition.

  2019cited by this paper
• Trends in Obesity and Severe Obesity Prevalence in US Youth and Adults by Sex and Age, 2007-2008 to 2015-2016

  2018cited by this paper
• 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019

  2018cited by this paper
• Redefining Hypertension - Assessing the New Blood-Pressure Guidelines.

  2018cited by this paper
• Conflicts of Interests, Authors, and Journals: New Challenges for a Persistent Problem

  2018cited by this paper
• Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline

  2018cited by this paper
• Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes d 2019

  2018cited by this paper
• Conflicts of Interest of Public Speakers at Meetings of the Anesthetic and Analgesic Drug Products Advisory Committee

  2018cited by this paper
• Economic Costs of Diabetes in the U.S. in 2017

  2018cited by this paper
• Financial Conflicts of Interest at FDA Drug Advisory Committee Meetings.

  2018cited by this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019

  2018cited by this paper
• Disclosure is Inadequate as a Solution to Managing Conflicts of Interest in Human Research

  2018cited by this paper
• Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians

  2018cited by this paper
• Electronic Health Records and the Disappearing Patient.

  2017cited by this paper
• National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey

  2017cited by this paper
• Standards of Medical Care in Diabetes-2017: Summary of Revisions.

  2017cited by this paper
• Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes d 2018

  2017cited by this paper
• 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018

  2017cited by this paper
• Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?

  2017cited by this paper
• Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes.

  2017cited by this paper
• 5. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes—2018

  2017cited by this paper
• Statin Use for the Primary Prevention of Cardiovascular Disease in Adults.

  2017cited by this paper
• ‘This is what we got, what would you like?’: Aligning and unaligning academic-industry relations

  2017cited by this paper
• Marketing trials, marketing tricks — how to spot them and how to stop them

  2017cited by this paper
• Early Worsening of Renal Function After Treatment with Antihyperglycemic Drugs: A Consistent Finding in Large-Scale Trials.

  2017cited by this paper
• Industry sponsorship and research outcome.

  2017cited by this paper
• Pharmocracy: Value, Politics, and Knowledge in Global Biomedicine

  2017cited by this paper
• In search of results: anthropological interrogations of evidence-based global health

  2017cited by this paper
• “Unsettling circularity”: Clinical trial enrichment and the evidentiary politics of chronic pain

  2017cited by this paper
• CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.

  2017cited by this paper
• Debates about Conflict of Interest in Medicine: Deconstructing a Divided Discourse

  2017cited by this paper
• Speed, Safety, and Industry Funding — From PDUFA I to PDUFA VI

  2017cited by this paper
• Conflict of Interest and Medical Journals

  2017cited by this paper
• Foreskin and the molecular politics of risk

  2017cited by this paper
• A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data.

  2017cited by this paper
• Pioglitazone use and risk of bladder cancer: population based cohort study

  2016cited by this paper
• When is a point of view a conflict of interest?

  2016cited by this paper
• Reporting of financial conflicts of interest in clinical practice guidelines: a case study analysis of guidelines from the Canadian Medical Association Infobase

  2016cited by this paper
• Unsafe Drugs Were Prescribed More Than One Hundred Million Times in the United States Before Being Recalled

  2016cited by this paper
• The 2013 cholesterol guideline controversy: Would better evidence prevent pharmaceuticalization?

  2016cited by this paper
• Inoculating the electorate: a qualitative look at American corporatocracy and its influence on health communication

  2016cited by this paper
• The Disposable Author: How Pharmaceutical Marketing Is Embraced within Medicine's Scholarly Literature.

  2016cited by this paper
• Trends in National Institutes of Health Funding for Clinical Trials Registered in ClinicalTrials.gov.

  2015cited by this paper
• Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add‐on therapy in subjects with new‐onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial

  2015cited by this paper
• Productivity of authors in the field of diabetes: bibliographic analysis of trial publications

  2015cited by this paper
• Drugs for Life: How Pharmaceutical Companies Define Our Health

  2015cited by this paper
• WITHDRAWN: Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.

  2015cited by this paper
• A deviation from standard design? Clinical trials, research ethics committees, and the regulatory co-construction of organizational deviance

  2014cited by this paper
• The pursuit of preventive care for chronic illness: turning healthy people into chronic patients.

  2014cited by this paper
• The shipwreck of the singular

  2014cited by this paper
• Life expectancy at birth

  2014cited by this paper
• The epidemic of pre-diabetes: the medicine and the politics

  2014cited by this paper
• More than a billion people taking statins?: Potential implications of the new cardiovascular guidelines.

  2014cited by this paper
• Revisiting financial conflicts of interest in FDA advisory committees.

  2014cited by this paper
• Too Much Medicine: The epidemic of pre-diabetes: the medicine and the politics

  2014cited by this paper
• The epidemic of pre-diabetes: the medicine and the politics

  2014cited by this paper
• Evidence‐Based Medicine or Cookbook Medicine? Addressing Concerns over the Standardization of Care

  2014cited by this paper
• Economic Costs of Diabetes in the U.S. in 2012

  2013cited by this paper
• Expanding Disease Definitions in Guidelines and Expert Panel Ties to Industry: A Cross-sectional Study of Common Conditions in the United States

  2013cited by this paper
• Quality of Clinical Practice Guidelines for Glycemic Control in Type 2 Diabetes Mellitus

  2013cited by this paper
• Being ‘evidence-based’ in the absence of evidence: The management of non-evidence in guideline development

  2013influential reference
• Standards of Medical Care in Diabetes—2014

  2013cited by this paper
• Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.

  2013cited by this paper
• Built for speed

  2013cited by this paper
• Rosiglitazone: a case of regulatory hubris

  2013cited by this paper
• Conflicts of Interest among Authors of Clinical Practice Guidelines for Glycemic Control in Type 2 Diabetes Mellitus

  2013cited by this paper
• “Tight Control” in Geriatrics: The Emperor Wears a Thong

  2012cited by this paper
• Drugs for Life: How Pharmaceutical Companies Define Our Health

  2012cited by this paper
• Industry sponsorship and research outcome.

  2012cited by this paper
• Changing health care quality paradigms: the rise of clinical guidelines and quality measures in American medicine.

  2012cited by this paper
• A Review and Critical Analysis of Professional Societies’ Guidelines for Pharmacologic Management of Type 2 Diabetes Mellitus

  2012cited by this paper
• The Changing Face of Chronic Illness Management in Primary Care: A Qualitative Study of Underlying Influences and Unintended Outcomes

  2012cited by this paper
• Basal insulin and cardiovascular and other outcomes in dysglycemia.

  2012cited by this paper
• Science, politics, and health in the brave new world of pharmaceutical carcinogenic risk assessment: Technical progress or cycle of regulatory capture?

  2012cited by this paper
• The pharmaceuticalisation of society? A framework for analysis.

  2011cited by this paper
• The idolatry of the surrogate

  2011cited by this paper
• Surrogates under scrutiny: fallible correlations, fatal consequences

  2011cited by this paper
• The inverse benefit law: how drug marketing undermines patient safety and public health.

  2011cited by this paper
• Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials

  2011cited by this paper
• Long-term effects of intensive glucose lowering on cardiovascular outcomes.

  2011cited by this paper
• Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study

  2011cited by this paper

• Biopolitics at the Nexus of Chronic and Infectious Diseases

  2025influential citation
• Global implications of diabetes biomedicalization

  2025influential citation
• Noninferiority and Efficiency/Revenue Facilitation (NERF) Endpoints : Shifting Grounds of Argument in Health AI Interventional Studies.

  2025cites this paper
• Prepregnancy Health Care Engagement Among American Indian and Alaska Native People Before and After the Affordable Care Act

  2024cites this paper
• Drivers of medicalization in the Canadian Adult Obesity Clinical Practice Guidelines

  2022cites this paper
• The Pensive Gaze

  2021cites this paper